Centre National De La Recherche Scientifique

Agence Nationale De Valorisation De La Recherche (anvar)

Rhone-poulenc Sante

L'oreal

Agence Nationale De Valorisation De La Recherche

Adir Et Compagnie

Hoechst Aktiengesellschaft

Roussel Uclaf

Societe L'oreal Sa

Societe De Conseils De Recherches Et D'applications Scientifiques

Madaus Ag

Sanofi

Pierre Potier

Claude Thal

Daniel Guenard

Nicole Langlois

Yves Langlois

Thierry Sevenet

Catherine Guillou

Henri P Husson

Francoise Gueritte-Voegelein

Ming Li

Eric Pilleux

Dolor Renko

Michel Colin

Pierre Lestage

Jean Lepagnol

Jean-Daniel Brion

Robert H Dodd

Luc Demuynck

Jean-Gilles Parmentier

Pierre Mangeney

Jean-Pierre Zanetta

Jean Rossier

Marie-Madeleine Portier

Hamid Abdul Hadi

Catherine Quirosa-Guillou

Emmanuel Gras

Monique Sensenbrenner

Herbert Koenig

Janine Koenig

Christiane Poupat

Alain Ahond

Pascal Schmitt

Jean-Francedillaois Pujol

Francoise Gueritte

Hubert Schaller

Jean-Luc Beunard

Lionel Breton

Francoise Delevallee

Nathalie Pineau

Yolande Herve

Joanna Bakala

Jamal Ouazzani

Wolf Grimminger

Alain Valla

Yves Christen

Gilbert Dorey

Michel Giraud

Karl P Odenthal

Ratremaniaina Z Andriamialisoa

Nobumichi-André Sasaki

Gisèle Franck

Zo Andriamialisoa

Lia P De Carvalho

Richard Besselievre

Maria Concepcion Achab Garcia Alvarez

Nobumichi Andre Sasaki

Martine Li

Josiane Thierry

Derek Barton

Michele Pusset

Pierre Laboute

Dominique Laurent

Jacques Pusset

Odile Thoison

Emile Benechie

Xavier Doisy

Qian Wang-Zhu

Lioudmila Ermolenko

Naima Bakrim Nhiri

Jean-Pierre Cosson

Olivier Boye

Laurent Dubois

Lia Prado De Carvalho

Klaus Goler

Laurent Ettouati

Qian Wang

Fran&ccedil;oise Picot

Aude Mary

Patrick Trouilleux

Raphaël Sole

Naïma Bakrim Nhiri

The invention relates to a compound having general formula I, wherein: X represents CH, C&#x2550;O, C&#x2550;S or CHOH, Rrepresents an amino acid optionally substituted by one or more halogen atoms, or by one or more CFgroups and n=0.1 or 2, or Rrepresents a peptide containing two amino acids, each amino acid being optionally substituted by one or more halogen atoms, or by one or more CFgroups and n=0 or 1, or XRrepresent POH or SOH and n=0.1 or 2; Rrepresents H, XR1, an alkyl group at C-C, an aralkyl group at C-Cor an aryl group, whereby the alkyl, aralkyl and aryl groups can be substituted by an amine NH, a carboxylic group COOH, one or more halogen atoms. 

Age inhibitors

The invention relates to a method for the synthesis of galanthamine, the derivatives and analogues thereof of formula (1) where R=a hydrogen atom, R=a hydroxy group, Rand Rtogether form &#x2550;O, R, R, and Rindependently=a hydrogen atom, a hydroxy group or a (C-C)alkoxy group, R&#x2550;H, (C-C)alkyl, (CH)NRR, or &#x2014;(CH)NRRRwhere n=1 to 12, Z=two hydrogen atoms, or an oxygen atom and X=an oxygen, sulphur or nitrogen atom, or a &#x2014;SO, &#x2014;SO, or &#x2014;NRgroup where Ris as defined above or is an amine protecting group.

Total synthesis of galanthamine, analogues and derivatives thereof

The invention concerns a method for preparing a-amino acids of general formula (2S-1) wherein: the group R1 represents a hydrogen atom, a group protecting the amino group or a group of formula &#x2014;COOR2 wherein the group R2 represents a C1-C6 alkyl group, an aryl or aralkyl group. The invention also concerns a-amino acids of general formula (2S-1) wherein the group R1 represents a group protecting the amino group or a group of formula &#x2014;COOR2 wherein the group R2 represents a C1-C6 alkyl group, an aryl or aralkyl group and their use as medicine.

Method for preparing (2S, 3R, 4S)-4-hydroxyisoleucine and analogues thereof

The invention relates to a method for the synthesis of galanthamifle, the derivatives and analogues thereof of formula (1) where R=a hydrogen atom. R=a hydroxy group, Rand Rtogether form &#x2550;O, R, R, and Rindependently=a hydrogen atom, a hydroxy group or a (C&#x2013;C)alkoxy group, R&#x2550;H, (C&#x2013;C)alkyl, (CH)NRR, or &#x2014;(CH)N'RRRwhere n=1 to 12, Z=two hydrogen atoms, or an oxygen atom and X=an oxygen, sulphur or nitrogen atom, or a &#x2014;SO, &#x2014;SO, or &#x2014;NRgroup where Ris as defined above or is an amine protecting group 

10-Hydroxy-2-decenoic acid compounds, particularly the 10-hydroxydec-2-enoates, are well suited for promoting desquamation of human skin and/or stimulating epidermal renewal and thus combating intrinsic and/or extrinsic cutaneous aging.

10-hydroxy-2-decenoic acid compounds for promoting desquamation/epidermal renewal of the skin and/or combating skin aging

Galanthamine derivatives, and their pharmaceutical compositions

The invention relates to the .beta.-methylene aldehydes of formula: ##STR1## in which: R.sub.1 and R.sub.2, which may be identical or different, are chosen from a hydrogen atom and optionally substituted carboacyclic, radicals,

.beta.-methylene aldehydes and preparation of compounds of interest by

Guanidine derivatives are provided useful for promoting growth, repair and regeneration of a neuronal axon and for treating neuropathies and myopathies. The compounds have the formula: ##STR1## wherein R.sub.1 is an isopropyl radical, a benzyl radical which is optionally substituted by one or more (C.sub.1 -C.sub.6)alkoxy radicals or a radical: ##STR2## R.sub.2, R.sub.3 and R.sub.4 together with the nitrogen atoms to which they are attached and the carbon atom to which the said nitrogen atoms are attached form a pyrimidine ring of formula II or a pyrimidinium ring of formula IIa: ##STR3##

Compounds having a guanidine structure and pharmaceutical composition

A compound selected from those of general formula (I): ##STR1## wherein A represents a bivalent radical ##STR2## and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and Z are as defined in the description, the isomers and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of depression and anxiety.

Benzopyrrolizinoquinolizinones

A compound selected from those of general formula (I): ##STR1## wherein A represents a bivalent radical selected from ##STR2## and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and Z are as defined in the description,

EburnanE analogues

Compounds derived from 6-azaindoles as ligands of the benzodiazepine

This invention relates to a novel 7-deacetoxy baccatine IV derivative having formula (I): ##STR1## the preparation thereof from taxine B, and its use in preparing biologically active products. In said formula (I), R is a hydrogen atom or acetyl radical and R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are hydroxy-function protective groupings (preferably acetonides).

7-deacetoxy beccatine IV derivative and preparation and use thereof

Compounds having a guanidine structure

A depigmenting cosmetic or dermatological composition containing, as active ingredient, at least one di- or tri-caffeoylquinic acid corresponding to general formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 represent a hydrogen atom or the CAF radical corresponding to the formula: ##STR2## provided that at least two, and at most three, of the R.sub.1, R.sub.2, R.sub.3, and R.sub.4 radicals represent the CAF radical, but excluding R.sub.1 and R.sub.2 as representing the CAF radical and R.sub.2 and R.sub.3 as representing a hydrogen atom, or a mixture of said caffeoylquinic acids.

Depigmenting cosmetic and/or dermatological composition containing a di-

A depigmenting cosmetic or dermatological composition containing, as active ingredient, at least one di- or tri-caffeoylquinic acid corresponding to general formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 represent a hydrogen atom or the CAF radical corresponding to the formula: ##STR2## provided that at least two, and at most three, of the R.sub.1, R.sub.2, R.sub.3, and R.sub.4 radicals represent the CAF radical, but excluding R.sub.1 and R.sub.4 as representing the CAF radical and R.sub.2 and R.sub.3 as representing a hydrogen atom, or a mixture of said caffeoylquinic acids.

Growing community of inventors

Paris, France

Pierre Potier